Helicos Aims to Position Platform for 'Large' Opportunity in Diagnostic Sequencing

In a presentation posted on Helicos' website earlier this month, Stan Lapidus, the company's co-founder and chairman, said the firm's platform offers "simplified sample prep, easy interpretation, and high throughput," allowing Helicos to pursue diagnostic applications, whereas competing second-generation sequencing systems have "limitations on throughput, cost, and complexity of sample prep."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.